129722-23-2

Basic information

• Product Name: 7-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one
• Synonyms: 7-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one
• CAS NO: 129722-23-2
• Molecular Weight: 409.528
• Mol File: 129722-23-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 7-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one(129722-23-2)
• EPA Substance Registry System: 7-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one(129722-23-2)

Safety Data

• Hazardous Substances Data: 129722-23-2(Hazardous Substances Data)

Upstream product

• 35386-24-4 1-(2-Methoxyphenyl)piperazine 
• 129722-34-5 7-(4-bromobutoxy)-3,4-dihydro-2(1H)-quinolinone 
• 5464-78-8 1-(2-methoxyphenyl)piperazine hydrochloride 
• 22246-18-0 7-hydroxy-3,4-dihydro-2-(1H)-quinolinone 

Downstream Products

• 1085927-91-8 7-(4-(4-(2-hydroxyphenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one 

Relevant articles and documents

Synthesis and characterization of selective dopamine D2 receptor ligands using aripiprazole as the lead compound

A series of compounds structurally related to aripiprazole (1), an atypical antipsychotic and antidepressant used clinically for the treatment of schizophrenia, bipolar disorder, and depression, have been prepared and evaluated for affinity at D2-lik

Novel antipsychotic agents with dopamine autoreceptor agonist properties: Synthesis and pharmacology of 7-[4-(4-phenyl-1- piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives

To develop a novel antipsychotic agent which is an agonist of dopamine (DA) autoreceptors and an antagonist of postsynaptic DA receptors, a series of 7-[4-[4-(substituted phenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)- quinolinones was synthesized and their dual activities were examined. The postsynaptic DA receptor antagonistic activities of the compounds were evaluated by their ability to inhibit stereotypy induced by apomorphine in mice, and the autoreceptor agonist activities were determined by their effects on the γ-butyrolactone (GBL)-induced increase in L- dihydroxyphenylalanine (DOPA) synthesis in the mouse brain. Many compounds inhibited the stereotypic behavior, and several compounds reversed the GBL- induced increase in the DOPA synthesis. Among them, 7-[4-[4-(2,3- dichlorophenyl)-l-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone (28, aripiprazole, OPC-14597) was found to have these two activities. This compound reversed the GBL-induced DOPA synthesis (ED50 values of 5.1 μmol/kg po) and inhibited the APO induced stereotypy (ED50 values of 0.6 μmol/kg po). Compound 28 induced catalepsy at 10 times higher dose than that required for the antagonism of APO-induced stereotypy (ED50 value of 7.8 μmol/kg po).